Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

NCT01788020 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT01788020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01788020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Lead sponsor
University of Ulm
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2013
Completion date
April 30, 2024
Enrollment
202 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

waldenström's macroglobulinemia